The HERA Trial: Cardiac Events at 8 years median follow-up

TITLE OF PUBLICATION

Trastuzumab-associated cardiac events at 8 years of median follow-up in the HERceptin Adjuvant Trial (HERA BIG 1-01)

AUTHORS

Evandro de Azambuja, Marion J. Procter, Dirk J. van Veldhuisen, Dominique Agbor-Tarh, Otto Metzger-Filho, Jutta Steinseifer, Michael Untch, Ian E. Smith, Luca Gianni, Jose Baselga, Christian Jackisch, David A. Cameron, Richard Bell, Brian Leyland-Jones, Mitch Dowsett, Richard D. Gelber, Martine J. Piccart-Gebhart, Thomas M. Suter

PUBLICATION REFERENCE

Journal of Clinical Oncology | Volume 32 | Issue 20 | Pages 2159-2165 | 10 July 2014

MORE PUBLICATIONS FROM FRONTIER SCIENCE SCOTLAND

ALTTO | ESMO Open

ALTTO | ESMO Open

Final 10-year analysis of the ALTTO trial exploring dual anti-HER2 blockade with lapatinib + trastuzumab compared to trastuzumab alone.

read more
APHINITY | Journal of Clinical Oncology

APHINITY | Journal of Clinical Oncology

Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update

read more
OlympiA results in the subset of patients from Japan

OlympiA results in the subset of patients from Japan

The consistency of results between the subset of patients from Japan and the global OlympiA population supports the clinical benefit of adjuvant olaparib for patients with gBRCA1/2pv and HER2-negative, high-risk eBC in Japan after completion of local treatment and neoadjuvant or adjuvant CT.

read more